435 related articles for article (PubMed ID: 21887711)
1. Parkinson's disease and α-synuclein expression.
Devine MJ; Gwinn K; Singleton A; Hardy J
Mov Disord; 2011 Oct; 26(12):2160-8. PubMed ID: 21887711
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery.
Lee VM; Trojanowski JQ
Neuron; 2006 Oct; 52(1):33-8. PubMed ID: 17015225
[TBL] [Abstract][Full Text] [Related]
3. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
Olanow CW; Brundin P
Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
[TBL] [Abstract][Full Text] [Related]
4. The role of posttranslational modifications of α-synuclein and LRRK2 in Parkinson's disease: Potential contributions of environmental factors.
Pajarillo E; Rizor A; Lee J; Aschner M; Lee E
Biochim Biophys Acta Mol Basis Dis; 2019 Aug; 1865(8):1992-2000. PubMed ID: 30481588
[TBL] [Abstract][Full Text] [Related]
5. α-Synuclein and Parkinsonism: Updates and Future Perspectives.
Rosborough K; Patel N; Kalia LV
Curr Neurol Neurosci Rep; 2017 Apr; 17(4):31. PubMed ID: 28324300
[TBL] [Abstract][Full Text] [Related]
6. Influence of microRNA deregulation on chaperone-mediated autophagy and α-synuclein pathology in Parkinson's disease.
Alvarez-Erviti L; Seow Y; Schapira AH; Rodriguez-Oroz MC; Obeso JA; Cooper JM
Cell Death Dis; 2013 Mar; 4(3):e545. PubMed ID: 23492776
[TBL] [Abstract][Full Text] [Related]
7. Physiological and pathological properties of alpha-synuclein.
Tofaris GK; Spillantini MG
Cell Mol Life Sci; 2007 Sep; 64(17):2194-201. PubMed ID: 17605001
[TBL] [Abstract][Full Text] [Related]
8. Pathological roles of α-synuclein in neurological disorders.
Vekrellis K; Xilouri M; Emmanouilidou E; Rideout HJ; Stefanis L
Lancet Neurol; 2011 Nov; 10(11):1015-25. PubMed ID: 22014436
[TBL] [Abstract][Full Text] [Related]
9. Experimental animal models of Parkinson's disease: A transition from assessing symptomatology to α-synuclein targeted disease modification.
Ko WKD; Bezard E
Exp Neurol; 2017 Dec; 298(Pt B):172-179. PubMed ID: 28764902
[TBL] [Abstract][Full Text] [Related]
10. Emerging pathways in genetic Parkinson's disease: tangles, Lewy bodies and LRRK2.
Devine MJ; Lewis PA
FEBS J; 2008 Dec; 275(23):5748-57. PubMed ID: 19021752
[TBL] [Abstract][Full Text] [Related]
11. Molecular mechanisms of alpha-synuclein neurodegeneration.
Waxman EA; Giasson BI
Biochim Biophys Acta; 2009 Jul; 1792(7):616-24. PubMed ID: 18955133
[TBL] [Abstract][Full Text] [Related]
12. Pathogenic Impact of α-Synuclein Phosphorylation and Its Kinases in α-Synucleinopathies.
Kawahata I; Finkelstein DI; Fukunaga K
Int J Mol Sci; 2022 Jun; 23(11):. PubMed ID: 35682892
[TBL] [Abstract][Full Text] [Related]
13. Synphilin isoforms and the search for a cellular model of lewy body formation in Parkinson's disease.
Eyal A; Engelender S
Cell Cycle; 2006 Sep; 5(18):2082-6. PubMed ID: 16969096
[TBL] [Abstract][Full Text] [Related]
14. Mutation in the alpha-synuclein gene and sporadic Parkinson's disease, Alzheimer's disease, and dementia with lewy bodies.
Higuchi S; Arai H; Matsushita S; Matsui T; Kimpara T; Takeda A; Shirakura K
Exp Neurol; 1998 Sep; 153(1):164-6. PubMed ID: 9743579
[TBL] [Abstract][Full Text] [Related]
15. How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease?
Volpicelli-Daley LA; Kirik D; Stoyka LE; Standaert DG; Harms AS
J Neurochem; 2016 Oct; 139 Suppl 1(Suppl 1):131-155. PubMed ID: 27018978
[TBL] [Abstract][Full Text] [Related]
16. Targeting alpha-synuclein for the treatment of Parkinson's disease.
Rohn TT
CNS Neurol Disord Drug Targets; 2012 Mar; 11(2):174-9. PubMed ID: 22483285
[TBL] [Abstract][Full Text] [Related]
17. Alpha-synuclein at the nexus of genes and environment: the impact of environmental enrichment and stress on brain health and disease.
Wassouf Z; Schulze-Hentrich JM
J Neurochem; 2019 Sep; 150(5):591-604. PubMed ID: 31165472
[TBL] [Abstract][Full Text] [Related]
18. α-Synuclein and Lewy pathology in Parkinson's disease.
Kalia LV; Kalia SK
Curr Opin Neurol; 2015 Aug; 28(4):375-81. PubMed ID: 26110807
[TBL] [Abstract][Full Text] [Related]
19. The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates.
Wakabayashi K; Tanji K; Mori F; Takahashi H
Neuropathology; 2007 Oct; 27(5):494-506. PubMed ID: 18018486
[TBL] [Abstract][Full Text] [Related]
20. Familial Mutations and Post-translational Modifications of UCH-L1 in Parkinson's Disease and Neurodegenerative Disorders.
Lee YC; Hsu SD
Curr Protein Pept Sci; 2017; 18(7):733-745. PubMed ID: 26899237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
